BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone415-506-6700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.49 billion
Profitability
Miscellaneous
Employees2,849
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions
What is BioMarin Pharmaceutical's stock symbol?
BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."
How were BioMarin Pharmaceutical's earnings last quarter?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Thursday, April, 25th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The biotechnology company earned $400.70 million during the quarter, compared to the consensus estimate of $389.95 million. BioMarin Pharmaceutical had a negative net margin of 5.90% and a negative return on equity of 2.97%. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.12 earnings per share. View BioMarin Pharmaceutical's Earnings History.
When is BioMarin Pharmaceutical's next earnings date?
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?
BioMarin Pharmaceutical updated its FY 2019 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.68-1.75 billion, compared to the consensus revenue estimate of $1.69 billion.
What price target have analysts set for BMRN?
17 Wall Street analysts have issued 12 month target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $81.00 to $135.00. On average, they expect BioMarin Pharmaceutical's share price to reach $116.00 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.
What is the consensus analysts' recommendation for BioMarin Pharmaceutical?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.
What are Wall Street analysts saying about BioMarin Pharmaceutical stock?
Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)
- 2. According to Zacks Investment Research, "BioMarin missed estimates for both earnings and sales in Q4. BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, on the back of strong demand trends. Its newest product, Palynziq’s U.S. launch is progressing well. Its rare disease pipeline is also progressing well. Growing pipeline focus toward gene therapy agents is encouraging However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Moreover, Naglazyme and Vimzin revenues vary on a quarterly basis, primarily owing to infrequent ordering patterns from some countries, mainly Brazil. Meanwhile, BioMarin is facing a generic threat for Kuvan in 2020. The earlier-than-expected entry of generics will be a huge blow for the company." (3/1/2019)
Has BioMarin Pharmaceutical been receiving favorable news coverage?
News stories about BMRN stock have been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of BioMarin Pharmaceutical's key competitors?
Some companies that are related to BioMarin Pharmaceutical include Bayer (BAYRY), Shire (SHPG), Zoetis (ZTS), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA) and Genmab A/S (GNMSF).
What other stocks do shareholders of BioMarin Pharmaceutical own?
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the folowing people:
- Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
- Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
- Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
- Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
- Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)
Who are BioMarin Pharmaceutical's major shareholders?
BioMarin Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (7.92%), Jennison Associates LLC (6.93%), Viking Global Investors LP (2.86%), Goldman Sachs Group Inc. (1.21%), Geode Capital Management LLC (0.98%) and Pictet Asset Management Ltd. (0.76%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.
Which major investors are selling BioMarin Pharmaceutical stock?
BMRN stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Marshall Wace North America L.P., Frontier Capital Management Co. LLC, Hsbc Holdings PLC, Arrowgrass Capital Partners US LP, Manning & Napier Group LLC, DekaBank Deutsche Girozentrale and Parametric Portfolio Associates LLC. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.
Which major investors are buying BioMarin Pharmaceutical stock?
BMRN stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Renaissance Technologies LLC, First Trust Advisors LP, Goldman Sachs Group Inc., Natixis, Geode Capital Management LLC, Sumitomo Mitsui Trust Holdings Inc. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for BioMarin Pharmaceutical.
How do I buy shares of BioMarin Pharmaceutical?
Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioMarin Pharmaceutical's stock price today?
One share of BMRN stock can currently be purchased for approximately $87.47.
How big of a company is BioMarin Pharmaceutical?
BioMarin Pharmaceutical has a market capitalization of $15.66 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.
What is BioMarin Pharmaceutical's official website?
How can I contact BioMarin Pharmaceutical?
BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]
MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
